Ferrer-Marín Francisca, Bellosillo Beatriz, Martínez-Avilés Luz, Soler Gloria, Carbonell Pablo, Luengo-Gil Ginés, Caparrós Eva, Torregrosa José M, Besses Carlos, Vicente Vicente
Hematology and Medical Oncology Unit, Hospital Universitario Morales-Meseguer, Centro Regional de Hemodonación, C/Ronda de Garay, sn, 3003, Murcia, Spain.
J Hematol Oncol. 2013 Sep 8;6:68. doi: 10.1186/1756-8722-6-68.
We have characterized the molecular changes underlying the transformation of a JAK2V617F+-myelofibrosis with trisomy 8, into a JAK2V617F-negative leukemia. Leukemic clone did not carry JAK2V617F mutation, but showed ASXL1 mutation (R693X). This mutation was identified in a low percentage at diagnosis by next-generation sequencing. Using this technology in serial specimens during the follow-up, we observed a progressive expansion of the ASXL1-mutated minor clone, whereas the JAK2V617F+-clone carrying trisomy 8 decreased. Hematologic progression occurred simultaneously with an ASXL1-R693X-negative lung-cancer. This is the first report showing a clear association between the expansion of an ASXL1-mutated clone and the leukemic transformation of myelofibrosis.
我们已经描述了8号染色体三体的JAK2V617F+骨髓纤维化转变为JAK2V617F阴性白血病所潜在的分子变化。白血病克隆未携带JAK2V617F突变,但显示出ASXL1突变(R693X)。通过下一代测序在诊断时该突变的检出率较低。在随访期间对系列标本使用该技术,我们观察到ASXL1突变的小克隆进行性扩增,而携带8号染色体三体的JAK2V617F+克隆减少。血液学进展与ASXL1-R693X阴性肺癌同时发生。这是第一份显示ASXL1突变克隆扩增与骨髓纤维化白血病转化之间存在明确关联的报告。